Yervoy and Zelboraf accounted for two-thirds of malignant melanoma drug market in 2011; report
The launches of Bristol-Myers Squibb’s (NYSE: BMY) immunotherapy Yervoy (ipilimumab) and Roche (ROG: SIX)/Genentech/Chugai/Daiichi Sankyo BRAF inhibitor Zelboraf (vemurafenib) have transformed the treatment of advanced malignant melanoma and, in 2011, these agents accounted for two-thirds of total malignant melanoma sales, according to the latest findings of health care advisory firm Decision Resources.
Through 2021, the line-extension of these agents into the adjuvant setting, and launches of other emerging novel therapies will drive a robust 9% annual growth in the malignant melanoma drug market in the USA, France, Germany, Italy, Spain, the UK and Japan.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
| Headless Content Management with Blaze